Wakabayashi Takeshi, Wasano Koichiro, Nakamura Kohei, Hosoya Makoto, Kawano Ryutaro, Takamatsu Reika, Ueno Masafumi, Shimanuki Marie N, Tsuzuki Nobuyoshi, Nishiyama Takanori, Akiyama Takenori, Toda Masahiro, Nishihara Hiroshi, Ozawa Hiroyuki, Oishi Naoki
Department of Otorhinolaryngology, Head and Neck Surgery Keio University School of Medicine Tokyo Japan.
Department of Otorhinolaryngology, Head and Neck Surgery Tokai University School of Medicine Isehara Kanagawa Japan.
Laryngoscope Investig Otolaryngol. 2025 Sep 27;10(5):e70265. doi: 10.1002/lio2.70265. eCollection 2025 Oct.
To elucidate the genetic etiology of sporadic vestibular schwannomas (VSs) and investigate the correlation between inactivation mechanisms and preoperative clinical characteristics, including hearing function and tumor growth.
Nineteen patients who underwent VS resection at our otorhinolaryngology or neurosurgery department between June 2020 and March 2022 were included in this study. Whole-exome sequencing (WES) was performed to detect somatic changes in . Additionally, promoter methylation status and copy number changes were evaluated using methylation analysis and multiple ligation-dependent probe amplification (MLPA). Preoperative clinical data, including pure tone audiometry, speech discrimination scores, and tumor growth rates, were collected and analyzed for correlations with genetic findings.
WES identified somatic alterations in both alleles in 16 cases (84.2%). The addition of methylation analysis and MLPA confirmed biallelic inactivation in all cases. promoter methylation was suggested to be associated with hearing loss and tumor progression. A weak correlation between expression levels and tumor growth rate was observed ( = 0.21), while no significant correlation was found between expression and pure tone audiometry or speech discrimination scores.
Comprehensive genetic analyses, including WES, methylation analysis, and MLPA, are essential for identifying inactivation mechanisms in sporadic VSs. The findings suggest that methylation may contribute to variations in clinical presentation. Further studies with larger cohorts are necessary to clarify the role of epigenetic modifications in disease progression and their potential impact on patient management strategies.